Home › FDA approves Novo Nordisk's weight loss injection, Saxenda
 

Keywords :   


FDA approves Novo Nordisk's weight loss injection, Saxenda

2014-12-26 06:37:52| Biotech - Topix.net

Novo Nordisk today announced that the Food and Drug Administration has approved the new drug application for Saxenda , the first once-daily glucagon-like peptide-1 receptor agonist for chronic weight management. Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are overweight in the presence of at least one weight-related comorbid condition.

Tags: loss weight novo injection

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.05P&G Professional Expands Laundry Care Lineup with Tide Laundry Detergent, Downy Fabric Softener
21.05Tennesse Program to Provide Free Diapers to Families
21.05Atlantic Tropical Weather Outlook
21.05Eastern North Pacific Tropical Weather Outlook
21.05Online car retailer Cazoo enters administration
21.05Sherwin-Williams Launches Pipeclad Frac-Shun ERC Technology
21.05Kosas Launches Blush Is Life Collection
21.05Avery Dennison receives APR critical guidance for HDPE plastic
More »